Chief Financial Officer & Treasurer · GoodRx Holdings, Inc. (GDRX)

Christopher McGinnis

FY2025 is the first fiscal year CompBrief holds for Christopher McGinnis as a named executive officer of GoodRx; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$8,698,916

Compensation figures as of the proxy filed April 29, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-09-24.

Christopher McGinnis compensation by year

GoodRx Summary Compensation Table · the one fiscal year held
In US dollars, as GoodRx reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$454,808
Bonus$1,250,000
Stock awards$3,474,923
Option awards$3,499,997
Non-equity incentive$0
Pension and deferred compensation$0
All other$19,188
Total$8,698,916

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GoodRx Holdings, Inc. DEF 14A filed April 29, 2026, accession 0001809519-26-000091, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU716,479$1,941,658—
Option1,096,937—$4.85

Per the Outstanding Equity Awards at Fiscal Year-End table in GoodRx Holdings, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

6 Form 4 lines since the FY2025 proxy (filed April 29, 2026)
current to 2026-09-24 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-07-15Tax withholding—16,294$3.01198,310
2026-07-15Exercise or conversion—36,988—214,604
2026-07-15Exercise or conversion derivative—36,988$0.00369,877
2026-05-15Exercise or conversion derivative—44,779$0.00492,580
2026-05-15Tax withholding—19,726$2.49177,616
2026-05-15Exercise or conversion—44,779—197,342

The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

GoodRx’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Wendy BarnesChief Executive Officer & President$23,367,483
Christopher McGinnis · this pageChief Financial Officer & Treasurer$8,698,916

The full GoodRx compensation record

free company brief

This page is one person within GoodRx's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order GoodRx's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GoodRx's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy